| Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal L Du, YJ Li, M Fakih, RL Wiatrek, M Duldulao, Z Chen, P Chu, ... Nature communications 7 (1), 12326, 2016 | 104 | 2016 |
| Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer MG Fakih, DL Trump, CS Johnson, L Tian, J Muindi, AY Sunga International journal of colorectal disease 24, 219-224, 2009 | 104 | 2009 |
| A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors MG Fakih, DL Trump, JR Muindi, JD Black, RJ Bernardi, PJ Creaven, ... Clinical Cancer Research 13 (4), 1216-1223, 2007 | 104 | 2007 |
| Vitamin D compounds: clinical development as cancer therapy and prevention agents DL Trump, J Muindi, M Fakih, WD Yu, CS Johnson Anticancer research 26 (4A), 2551-2556, 2006 | 93 | 2006 |
| Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C MG Fakih, L Salvatore, T Esaki, DP Modest, DP Lopez-Bravo, J Taieb, ... New England Journal of Medicine 389 (23), 2125-2139, 2023 | 92 | 2023 |
| Reliability, validity, and feasibility of a computer-based geriatric assessment for older adults with cancer A Hurria, C Akiba, J Kim, D Mitani, M Loscalzo, V Katheria, M Koczywas, ... Journal of oncology practice 12 (12), e1025-e1034, 2016 | 92 | 2016 |
| Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines AB Benson, JP Arnoletti, T Bekaii-Saab, E Chan, YJ Chen, MA Choti, ... Journal of the National Comprehensive Cancer Network 10 (4), 449-454, 2012 | 92 | 2012 |
| Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer K Raghav, JM Loree, JS Morris, MJ Overman, R Yu, F Meric-Bernstam, ... JCO Precision Oncology 3, 1-13, 2019 | 90 | 2019 |
| A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study RV Iyer, J Gibbs, B Kuvshinoff, M Fakih, J Kepner, N Soehnlein, ... Annals of Surgical Oncology 14, 3202-3209, 2007 | 90 | 2007 |
| Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review M Fakih, CS Johnson, DL Trump Urology 60 (4), 553-561, 2002 | 90 | 2002 |
| Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable … C Wang, J Sandhu, C Ouyang, J Ye, PP Lee, M Fakih JAMA network Open 4 (8), e2118416-e2118416, 2021 | 82 | 2021 |
| HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. KPS Raghav, MJ Overman, R Yu, F Meric-Bernstam, D Menter, BK Kee, ... Journal of Clinical Oncology 34 (15_suppl), 3517-3517, 2016 | 82 | 2016 |
| Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: a series of six cases M Fakih, D Schiff, R Erlich, TF Logan Annals of oncology 12 (8), 1173-1177, 2001 | 82 | 2001 |
| Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy AR Parikh, Y He, TS Hong, RB Corcoran, JW Clark, DP Ryan, L Zou, ... The Oncologist 24 (10), 1340-1347, 2019 | 79 | 2019 |
| Management of Anal Cancer in 2010-Part 1: Overview, Screening, and Diagnosis A Abbas, G Yang, M Fakih Oncology; San Francisco 24 (4), 364, 2010 | 79 | 2010 |
| Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer C Wang, D Chevalier, J Saluja, J Sandhu, C Lau, M Fakih The oncologist 25 (8), e1188-e1194, 2020 | 78 | 2020 |
| TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer: a randomized phase 1b/2 trial CS Fuchs, M Fakih, L Schwartzberg, AL Cohn, L Yee, L Dreisbach, ... Cancer 119 (24), 4290-4298, 2013 | 77 | 2013 |
| A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. S Siena, M Di Bartolomeo, KPS Raghav, T Masuishi, F Loupakis, ... Journal of Clinical Oncology 38 (15_suppl), 4000-4000, 2020 | 73 | 2020 |
| A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer MG Fakih, L Pendyala, G Fetterly, K Toth, JA Zwiebel, I Espinoza-Delgado, ... Clinical cancer research 15 (9), 3189-3195, 2009 | 73 | 2009 |
| Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome M Fakih, C Ouyang, C Wang, TY Tu, MC Gozo, M Cho, M Sy, ... The Journal of clinical investigation 129 (10), 4464-4476, 2019 | 71 | 2019 |
